(TWST) Twist Bioscience - Ratings and Ratios
Synthetic Dna,Gene,Silicon Chips
TWST EPS (Earnings per Share)
TWST Revenue
Description: TWST Twist Bioscience
Twist Bioscience Corp (NASDAQ:TWST) is a biotechnology company listed on the NASDAQ exchange, operating in the biotechnology sub-industry. The companys stock performance has been volatile, with a beta of 2.368 indicating high sensitivity to market fluctuations.
The stocks current price is $27.63, significantly lower than its 52-week high of $54.07 and closer to its 52-week low of $25.00. The moving averages (SMA20: $32.84, SMA50: $34.13, SMA200: $40.36) suggest a downtrend, indicating potential bearish sentiment among investors.
From a fundamental analysis perspective, Twist Bioscience Corp has a market capitalization of $1.563 billion. The absence of a price-to-earnings (P/E) ratio, both current and forward, suggests that the company is not profitable. The return on equity (RoE) is -18.45%, indicating significant losses relative to shareholder equity. Key drivers for the companys valuation include revenue growth, R&D expenses, and the successful development and commercialization of its biotechnology products.
To assess the companys potential, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating expense management will be crucial. Economic drivers like the demand for synthetic biology products, the competitive landscape, and regulatory developments in the biotechnology sector will also play a significant role in determining the companys future prospects.
A critical analysis would involve evaluating the companys cash burn rate, the potential for future profitability, and the impact of market volatility on its stock price. The high average trading volume of 1,061,996 shares indicates liquidity, making it easier for investors to buy and sell shares.
TWST Stock Overview
| Market Cap in USD | 1,528m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-10-31 |
TWST Stock Ratings
| Growth Rating | -60.3% |
| Fundamental | 32.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -51.0% |
| Analyst Rating | 4.17 of 5 |
TWST Dividends
Currently no dividends paidTWST Growth Ratios
| Growth Correlation 3m | -84.8% |
| Growth Correlation 12m | -82.3% |
| Growth Correlation 5y | -54.1% |
| CAGR 5y | -10.06% |
| CAGR/Max DD 3y | -0.14 |
| CAGR/Mean DD 3y | -0.31 |
| Sharpe Ratio 12m | -0.76 |
| Alpha | 0.06 |
| Beta | 0.122 |
| Volatility | 68.78% |
| Current Volume | 2313.2k |
| Average Volume 20d | 1404.2k |
| Stop Loss | 25.5 (-5.8%) |
| Signal | 1.63 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-85.2m TTM) > 0 and > 6% of Revenue (6% = 21.7m TTM) |
| FCFTA -0.11 (>2.0%) and ΔFCFTA 15.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 69.76% (prev 97.58%; Δ -27.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -51.1m > Net Income -85.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.2m) change vs 12m ago 5.19% (target <= -2.0% for YES) |
| Gross Margin 49.24% (prev 40.53%; Δ 8.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.53% (prev 46.26%; Δ 10.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -560.5 (EBITDA TTM -123.5m / Interest Expense TTM 243.0k) >= 6 (WARN >= 3) |
Altman Z'' -13.61
| (A) 0.39 = (Total Current Assets 339.8m - Total Current Liabilities 87.1m) / Total Assets 643.6m |
| (B) -2.01 = Retained Earnings (Balance) -1.29b / Total Assets 643.6m |
| warn (B) unusual magnitude: -2.01 — check mapping/units |
| (C) -0.21 = EBIT TTM -136.2m / Avg Total Assets 640.9m |
| (D) -7.82 = Book Value of Equity -1.29b / Total Liabilities 165.4m |
| Total Rating: -13.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.46
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -5.05% = -2.52 |
| 3. FCF Margin -19.09% = -7.16 |
| 4. Debt/Equity 0.20 = 2.48 |
| 5. Debt/Ebitda -0.76 = -2.50 |
| 6. ROIC - WACC (= -35.60)% = -12.50 |
| 7. RoE -18.45% = -2.50 |
| 8. Rev. Trend 99.09% = 7.43 |
| 9. EPS Trend 44.63% = 2.23 |
What is the price of TWST shares?
Over the past week, the price has changed by +7.93%, over one month by -3.35%, over three months by -22.72% and over the past year by -41.84%.
Is Twist Bioscience a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TWST is around 20.69 USD . This means that TWST is currently overvalued and has a potential downside of -23.6%.
Is TWST a buy, sell or hold?
- Strong Buy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TWST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40 | 47.7% |
| Analysts Target Price | 40 | 47.7% |
| ValueRay Target Price | 22.6 | -16.6% |
Last update: 2025-09-16 04:42
TWST Fundamental Data Overview
CCE Cash And Equivalents = 250.8m USD (Cash And Short Term Investments, last quarter)
P/S = 4.2171
P/B = 3.1948
Beta = 2.308
Revenue TTM = 362.3m USD
EBIT TTM = -136.2m USD
EBITDA TTM = -123.5m USD
Long Term Debt = 78.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 15.5m USD (from shortTermDebt, last quarter)
Debt = 93.8m USD (Calculated: Short Term 15.5m + Long Term 78.3m)
Net Debt = -123.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.37b USD (1.53b + Debt 93.8m - CCE 250.8m)
Interest Coverage Ratio = -560.5 (Ebit TTM -136.2m / Interest Expense TTM 243.0k)
FCF Yield = -5.05% (FCF TTM -69.2m / Enterprise Value 1.37b)
FCF Margin = -19.09% (FCF TTM -69.2m / Revenue TTM 362.3m)
Net Margin = -23.51% (Net Income TTM -85.2m / Revenue TTM 362.3m)
Gross Margin = 49.24% ((Revenue TTM 362.3m - Cost of Revenue TTM 183.9m) / Revenue TTM)
Tobins Q-Ratio = -1.06 (set to none) (Enterprise Value 1.37b / Book Value Of Equity -1.29b)
Interest Expense / Debt = 0.20% (Interest Expense 190.0k / Debt 93.8m)
Taxrate = 0.93% (191.0k / 20.6m)
NOPAT = -136.2m (EBIT -136.2m, no tax applied on loss)
Current Ratio = 3.90 (Total Current Assets 339.8m / Total Current Liabilities 87.1m)
Debt / Equity = 0.20 (Debt 93.8m / last Quarter total Stockholder Equity 478.2m)
Debt / EBITDA = -0.76 (Net Debt -123.2m / EBITDA -123.5m)
Debt / FCF = -1.36 (Debt 93.8m / FCF TTM -69.2m)
Total Stockholder Equity = 461.7m (last 4 quarters mean)
RoA = -13.24% (Net Income -85.2m, Total Assets 643.6m )
RoE = -18.45% (Net Income TTM -85.2m / Total Stockholder Equity 461.7m)
RoCE = -25.22% (Ebit -136.2m / (Equity 461.7m + L.T.Debt 78.3m))
RoIC = -29.50% (NOPAT -136.2m / Invested Capital 461.7m)
WACC = 6.10% (E(1.53b)/V(1.62b) * Re(6.46%)) + (D(93.8m)/V(1.62b) * Rd(0.20%) * (1-Tc(0.01)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.76%
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -69.2m)
EPS Correlation: 44.63 | EPS CAGR: 21.06% | SUE: 0.32 | # QB: 0
Revenue Correlation: 99.09 | Revenue CAGR: 20.66% | SUE: N/A | # QB: None
Additional Sources for TWST Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle